

# Global Idiopathic Pulmonary Fibrosis (IPF) Drug Market 2025 by Manufacturers, Regions, Type and Application, Forecast to 2031

<https://marketpublishers.com/r/G6C3AC13E253EN.html>

Date: June 2025

Pages: 70

Price: US\$ 3,480.00 (Single User License)

ID: G6C3AC13E253EN

## Abstracts

According to our (Global Info Research) latest study, the global Idiopathic Pulmonary Fibrosis (IPF) Drug market size was valued at US\$ 301 million in 2024 and is forecast to a readjusted size of USD 398 million by 2031 with a CAGR of 4.1% during review period.

These include nintedanib (Ofev®) and pirfenidone (Esbriet®). These medications are called anti-fibrotic agents, meaning that they have shown in clinical trials to slow down the rate of fibrosis or scarring in the lungs. These drugs are approved for patients with mild, moderate and severe IPF.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

This report is a detailed and comprehensive analysis for global Idiopathic Pulmonary Fibrosis (IPF) Drug market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.

#### Key Features:

Global Idiopathic Pulmonary Fibrosis (IPF) Drug market size and forecasts, in consumption value (\$ Million), sales quantity (K Units), and average selling prices (US\$/Unit), 2020-2031

Global Idiopathic Pulmonary Fibrosis (IPF) Drug market size and forecasts by region and country, in consumption value (\$ Million), sales quantity (K Units), and average selling prices (US\$/Unit), 2020-2031

Global Idiopathic Pulmonary Fibrosis (IPF) Drug market size and forecasts, by Type and by Application, in consumption value (\$ Million), sales quantity (K Units), and average selling prices (US\$/Unit), 2020-2031

Global Idiopathic Pulmonary Fibrosis (IPF) Drug market shares of main players, shipments in revenue (\$ Million), sales quantity (K Units), and ASP (US\$/Unit), 2020-2025

#### The Primary Objectives in This Report Are:

To determine the size of the total market opportunity of global and key countries

To assess the growth potential for Idiopathic Pulmonary Fibrosis (IPF) Drug

To forecast future growth in each product and end-use market

To assess competitive factors affecting the marketplace

This report profiles key players in the global Idiopathic Pulmonary Fibrosis (IPF) Drug market based on the following parameters - company overview, sales quantity, revenue,

price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Roche Holding AG, Boehringer Ingelheim International GmbH, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.

## Market Segmentation

Idiopathic Pulmonary Fibrosis (IPF) Drug market is split by Type and by Application. For the period 2020-2031, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.

### Market segment by Type

Nintedanib

Pirfenidone

### Market segment by Application

Hospital

Clinics

Others

### Major players covered

Roche Holding AG

Boehringer Ingelheim International GmbH

### Market segment by region, regional analysis covers

North America (United States, Canada, and Mexico)

Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)

Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)

South America (Brazil, Argentina, Colombia, and Rest of South America)

Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)

The content of the study subjects, includes a total of 15 chapters:

Chapter 1, to describe Idiopathic Pulmonary Fibrosis (IPF) Drug product scope, market overview, market estimation caveats and base year.

Chapter 2, to profile the top manufacturers of Idiopathic Pulmonary Fibrosis (IPF) Drug, with price, sales quantity, revenue, and global market share of Idiopathic Pulmonary Fibrosis (IPF) Drug from 2020 to 2025.

Chapter 3, the Idiopathic Pulmonary Fibrosis (IPF) Drug competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.

Chapter 4, the Idiopathic Pulmonary Fibrosis (IPF) Drug breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2020 to 2031.

Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2020 to 2031.

Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2020 to 2025. and Idiopathic Pulmonary Fibrosis (IPF) Drug market forecast, by regions, by Type, and by Application, with sales and revenue, from 2026 to 2031.

Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.

Chapter 13, the key raw materials and key suppliers, and industry chain of Idiopathic Pulmonary Fibrosis (IPF) Drug.

Chapter 14 and 15, to describe Idiopathic Pulmonary Fibrosis (IPF) Drug sales channel, distributors, customers, research findings and conclusion.

## Contents

### 1 MARKET OVERVIEW

#### 1.1 Product Overview and Scope

#### 1.2 Market Estimation Caveats and Base Year

#### 1.3 Market Analysis by Type

1.3.1 Overview: Global Idiopathic Pulmonary Fibrosis (IPF) Drug Consumption Value by Type: 2020 Versus 2024 Versus 2031

##### 1.3.2 Nintedanib

##### 1.3.3 Pirfenidone

#### 1.4 Market Analysis by Application

1.4.1 Overview: Global Idiopathic Pulmonary Fibrosis (IPF) Drug Consumption Value by Application: 2020 Versus 2024 Versus 2031

##### 1.4.2 Hospital

##### 1.4.3 Clinics

##### 1.4.4 Others

#### 1.5 Global Idiopathic Pulmonary Fibrosis (IPF) Drug Market Size & Forecast

1.5.1 Global Idiopathic Pulmonary Fibrosis (IPF) Drug Consumption Value (2020 & 2024 & 2031)

1.5.2 Global Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Quantity (2020-2031)

1.5.3 Global Idiopathic Pulmonary Fibrosis (IPF) Drug Average Price (2020-2031)

### 2 MANUFACTURERS PROFILES

#### 2.1 Roche Holding AG

##### 2.1.1 Roche Holding AG Details

##### 2.1.2 Roche Holding AG Major Business

2.1.3 Roche Holding AG Idiopathic Pulmonary Fibrosis (IPF) Drug Product and Services

2.1.4 Roche Holding AG Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)

##### 2.1.5 Roche Holding AG Recent Developments/Updates

#### 2.2 Boehringer Ingelheim International GmbH

##### 2.2.1 Boehringer Ingelheim International GmbH Details

##### 2.2.2 Boehringer Ingelheim International GmbH Major Business

2.2.3 Boehringer Ingelheim International GmbH Idiopathic Pulmonary Fibrosis (IPF) Drug Product and Services

2.2.4 Boehringer Ingelheim International GmbH Idiopathic Pulmonary Fibrosis (IPF)

Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share  
(2020-2025)

2.2.5 Boehringer Ingelheim International GmbH Recent Developments/Updates

### **3 COMPETITIVE ENVIRONMENT: IDIOPATHIC PULMONARY FIBROSIS (IPF) DRUG BY MANUFACTURER**

3.1 Global Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Quantity by Manufacturer  
(2020-2025)

3.2 Global Idiopathic Pulmonary Fibrosis (IPF) Drug Revenue by Manufacturer  
(2020-2025)

3.3 Global Idiopathic Pulmonary Fibrosis (IPF) Drug Average Price by Manufacturer  
(2020-2025)

3.4 Market Share Analysis (2024)

3.4.1 Producer Shipments of Idiopathic Pulmonary Fibrosis (IPF) Drug by  
Manufacturer Revenue (\$MM) and Market Share (%): 2024

3.4.2 Top 3 Idiopathic Pulmonary Fibrosis (IPF) Drug Manufacturer Market Share in  
2024

3.4.3 Top 6 Idiopathic Pulmonary Fibrosis (IPF) Drug Manufacturer Market Share in  
2024

3.5 Idiopathic Pulmonary Fibrosis (IPF) Drug Market: Overall Company Footprint  
Analysis

3.5.1 Idiopathic Pulmonary Fibrosis (IPF) Drug Market: Region Footprint

3.5.2 Idiopathic Pulmonary Fibrosis (IPF) Drug Market: Company Product Type  
Footprint

3.5.3 Idiopathic Pulmonary Fibrosis (IPF) Drug Market: Company Product Application  
Footprint

3.6 New Market Entrants and Barriers to Market Entry

3.7 Mergers, Acquisition, Agreements, and Collaborations

### **4 CONSUMPTION ANALYSIS BY REGION**

4.1 Global Idiopathic Pulmonary Fibrosis (IPF) Drug Market Size by Region

4.1.1 Global Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Quantity by Region  
(2020-2031)

4.1.2 Global Idiopathic Pulmonary Fibrosis (IPF) Drug Consumption Value by Region  
(2020-2031)

4.1.3 Global Idiopathic Pulmonary Fibrosis (IPF) Drug Average Price by Region  
(2020-2031)

4.2 North America Idiopathic Pulmonary Fibrosis (IPF) Drug Consumption Value (2020-2031)

4.3 Europe Idiopathic Pulmonary Fibrosis (IPF) Drug Consumption Value (2020-2031)

4.4 Asia-Pacific Idiopathic Pulmonary Fibrosis (IPF) Drug Consumption Value (2020-2031)

4.5 South America Idiopathic Pulmonary Fibrosis (IPF) Drug Consumption Value (2020-2031)

4.6 Middle East & Africa Idiopathic Pulmonary Fibrosis (IPF) Drug Consumption Value (2020-2031)

## **5 MARKET SEGMENT BY TYPE**

5.1 Global Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Quantity by Type (2020-2031)

5.2 Global Idiopathic Pulmonary Fibrosis (IPF) Drug Consumption Value by Type (2020-2031)

5.3 Global Idiopathic Pulmonary Fibrosis (IPF) Drug Average Price by Type (2020-2031)

## **6 MARKET SEGMENT BY APPLICATION**

6.1 Global Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Quantity by Application (2020-2031)

6.2 Global Idiopathic Pulmonary Fibrosis (IPF) Drug Consumption Value by Application (2020-2031)

6.3 Global Idiopathic Pulmonary Fibrosis (IPF) Drug Average Price by Application (2020-2031)

## **7 NORTH AMERICA**

7.1 North America Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Quantity by Type (2020-2031)

7.2 North America Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Quantity by Application (2020-2031)

7.3 North America Idiopathic Pulmonary Fibrosis (IPF) Drug Market Size by Country

7.3.1 North America Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Quantity by Country (2020-2031)

7.3.2 North America Idiopathic Pulmonary Fibrosis (IPF) Drug Consumption Value by Country (2020-2031)

7.3.3 United States Market Size and Forecast (2020-2031)

7.3.4 Canada Market Size and Forecast (2020-2031)

7.3.5 Mexico Market Size and Forecast (2020-2031)

## **8 EUROPE**

8.1 Europe Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Quantity by Type (2020-2031)

8.2 Europe Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Quantity by Application (2020-2031)

8.3 Europe Idiopathic Pulmonary Fibrosis (IPF) Drug Market Size by Country

8.3.1 Europe Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Quantity by Country (2020-2031)

8.3.2 Europe Idiopathic Pulmonary Fibrosis (IPF) Drug Consumption Value by Country (2020-2031)

8.3.3 Germany Market Size and Forecast (2020-2031)

8.3.4 France Market Size and Forecast (2020-2031)

8.3.5 United Kingdom Market Size and Forecast (2020-2031)

8.3.6 Russia Market Size and Forecast (2020-2031)

8.3.7 Italy Market Size and Forecast (2020-2031)

## **9 ASIA-PACIFIC**

9.1 Asia-Pacific Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Quantity by Type (2020-2031)

9.2 Asia-Pacific Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Quantity by Application (2020-2031)

9.3 Asia-Pacific Idiopathic Pulmonary Fibrosis (IPF) Drug Market Size by Region

9.3.1 Asia-Pacific Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Quantity by Region (2020-2031)

9.3.2 Asia-Pacific Idiopathic Pulmonary Fibrosis (IPF) Drug Consumption Value by Region (2020-2031)

9.3.3 China Market Size and Forecast (2020-2031)

9.3.4 Japan Market Size and Forecast (2020-2031)

9.3.5 South Korea Market Size and Forecast (2020-2031)

9.3.6 India Market Size and Forecast (2020-2031)

9.3.7 Southeast Asia Market Size and Forecast (2020-2031)

9.3.8 Australia Market Size and Forecast (2020-2031)

## **10 SOUTH AMERICA**

10.1 South America Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Quantity by Type (2020-2031)

10.2 South America Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Quantity by Application (2020-2031)

10.3 South America Idiopathic Pulmonary Fibrosis (IPF) Drug Market Size by Country

10.3.1 South America Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Quantity by Country (2020-2031)

10.3.2 South America Idiopathic Pulmonary Fibrosis (IPF) Drug Consumption Value by Country (2020-2031)

10.3.3 Brazil Market Size and Forecast (2020-2031)

10.3.4 Argentina Market Size and Forecast (2020-2031)

## **11 MIDDLE EAST & AFRICA**

11.1 Middle East & Africa Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Quantity by Type (2020-2031)

11.2 Middle East & Africa Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Quantity by Application (2020-2031)

11.3 Middle East & Africa Idiopathic Pulmonary Fibrosis (IPF) Drug Market Size by Country

11.3.1 Middle East & Africa Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Quantity by Country (2020-2031)

11.3.2 Middle East & Africa Idiopathic Pulmonary Fibrosis (IPF) Drug Consumption Value by Country (2020-2031)

11.3.3 Turkey Market Size and Forecast (2020-2031)

11.3.4 Egypt Market Size and Forecast (2020-2031)

11.3.5 Saudi Arabia Market Size and Forecast (2020-2031)

11.3.6 South Africa Market Size and Forecast (2020-2031)

## **12 MARKET DYNAMICS**

12.1 Idiopathic Pulmonary Fibrosis (IPF) Drug Market Drivers

12.2 Idiopathic Pulmonary Fibrosis (IPF) Drug Market Restraints

12.3 Idiopathic Pulmonary Fibrosis (IPF) Drug Trends Analysis

12.4 Porters Five Forces Analysis

12.4.1 Threat of New Entrants

12.4.2 Bargaining Power of Suppliers

12.4.3 Bargaining Power of Buyers

12.4.4 Threat of Substitutes

12.4.5 Competitive Rivalry

## **13 RAW MATERIAL AND INDUSTRY CHAIN**

13.1 Raw Material of Idiopathic Pulmonary Fibrosis (IPF) Drug and Key Manufacturers

13.2 Manufacturing Costs Percentage of Idiopathic Pulmonary Fibrosis (IPF) Drug

13.3 Idiopathic Pulmonary Fibrosis (IPF) Drug Production Process

13.4 Industry Value Chain Analysis

## **14 SHIPMENTS BY DISTRIBUTION CHANNEL**

14.1 Sales Channel

14.1.1 Direct to End-User

14.1.2 Distributors

14.2 Idiopathic Pulmonary Fibrosis (IPF) Drug Typical Distributors

14.3 Idiopathic Pulmonary Fibrosis (IPF) Drug Typical Customers

## **15 RESEARCH FINDINGS AND CONCLUSION**

## **16 APPENDIX**

16.1 Methodology

16.2 Research Process and Data Source

16.3 Disclaimer

## List Of Tables

### LIST OF TABLES

Table 1. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Consumption Value by Type, (USD Million), 2020 & 2024 & 2031

Table 2. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Consumption Value by Application, (USD Million), 2020 & 2024 & 2031

Table 3. Roche Holding AG Basic Information, Manufacturing Base and Competitors

Table 4. Roche Holding AG Major Business

Table 5. Roche Holding AG Idiopathic Pulmonary Fibrosis (IPF) Drug Product and Services

Table 6. Roche Holding AG Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Quantity (K Units), Average Price (US\$/Unit), Revenue (USD Million), Gross Margin and Market Share (2020-2025)

Table 7. Roche Holding AG Recent Developments/Updates

Table 8. Boehringer Ingelheim International GmbH Basic Information, Manufacturing Base and Competitors

Table 9. Boehringer Ingelheim International GmbH Major Business

Table 10. Boehringer Ingelheim International GmbH Idiopathic Pulmonary Fibrosis (IPF) Drug Product and Services

Table 11. Boehringer Ingelheim International GmbH Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Quantity (K Units), Average Price (US\$/Unit), Revenue (USD Million), Gross Margin and Market Share (2020-2025)

Table 12. Boehringer Ingelheim International GmbH Recent Developments/Updates

Table 13. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Quantity by Manufacturer (2020-2025) & (K Units)

Table 14. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Revenue by Manufacturer (2020-2025) & (USD Million)

Table 15. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Average Price by Manufacturer (2020-2025) & (US\$/Unit)

Table 16. Market Position of Manufacturers in Idiopathic Pulmonary Fibrosis (IPF) Drug, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2024

Table 17. Head Office and Idiopathic Pulmonary Fibrosis (IPF) Drug Production Site of Key Manufacturer

Table 18. Idiopathic Pulmonary Fibrosis (IPF) Drug Market: Company Product Type Footprint

Table 19. Idiopathic Pulmonary Fibrosis (IPF) Drug Market: Company Product Application Footprint

Table 20. Idiopathic Pulmonary Fibrosis (IPF) Drug New Market Entrants and Barriers to Market Entry

Table 21. Idiopathic Pulmonary Fibrosis (IPF) Drug Mergers, Acquisition, Agreements, and Collaborations

Table 22. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Consumption Value by Region (2020-2024-2031) & (USD Million) & CAGR

Table 23. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Quantity by Region (2020-2025) & (K Units)

Table 24. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Quantity by Region (2026-2031) & (K Units)

Table 25. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Consumption Value by Region (2020-2025) & (USD Million)

Table 26. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Consumption Value by Region (2026-2031) & (USD Million)

Table 27. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Average Price by Region (2020-2025) & (US\$/Unit)

Table 28. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Average Price by Region (2026-2031) & (US\$/Unit)

Table 29. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Quantity by Type (2020-2025) & (K Units)

Table 30. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Quantity by Type (2026-2031) & (K Units)

Table 31. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Consumption Value by Type (2020-2025) & (USD Million)

Table 32. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Consumption Value by Type (2026-2031) & (USD Million)

Table 33. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Average Price by Type (2020-2025) & (US\$/Unit)

Table 34. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Average Price by Type (2026-2031) & (US\$/Unit)

Table 35. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Quantity by Application (2020-2025) & (K Units)

Table 36. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Quantity by Application (2026-2031) & (K Units)

Table 37. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Consumption Value by Application (2020-2025) & (USD Million)

Table 38. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Consumption Value by Application (2026-2031) & (USD Million)

Table 39. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Average Price by Application

(2020-2025) & (US\$/Unit)

Table 40. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Average Price by Application (2026-2031) & (US\$/Unit)

Table 41. North America Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Quantity by Type (2020-2025) & (K Units)

Table 42. North America Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Quantity by Type (2026-2031) & (K Units)

Table 43. North America Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Quantity by Application (2020-2025) & (K Units)

Table 44. North America Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Quantity by Application (2026-2031) & (K Units)

Table 45. North America Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Quantity by Country (2020-2025) & (K Units)

Table 46. North America Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Quantity by Country (2026-2031) & (K Units)

Table 47. North America Idiopathic Pulmonary Fibrosis (IPF) Drug Consumption Value by Country (2020-2025) & (USD Million)

Table 48. North America Idiopathic Pulmonary Fibrosis (IPF) Drug Consumption Value by Country (2026-2031) & (USD Million)

Table 49. Europe Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Quantity by Type (2020-2025) & (K Units)

Table 50. Europe Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Quantity by Type (2026-2031) & (K Units)

Table 51. Europe Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Quantity by Application (2020-2025) & (K Units)

Table 52. Europe Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Quantity by Application (2026-2031) & (K Units)

Table 53. Europe Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Quantity by Country (2020-2025) & (K Units)

Table 54. Europe Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Quantity by Country (2026-2031) & (K Units)

Table 55. Europe Idiopathic Pulmonary Fibrosis (IPF) Drug Consumption Value by Country (2020-2025) & (USD Million)

Table 56. Europe Idiopathic Pulmonary Fibrosis (IPF) Drug Consumption Value by Country (2026-2031) & (USD Million)

Table 57. Asia-Pacific Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Quantity by Type (2020-2025) & (K Units)

Table 58. Asia-Pacific Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Quantity by Type (2026-2031) & (K Units)

Table 59. Asia-Pacific Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Quantity by Application (2020-2025) & (K Units)

Table 60. Asia-Pacific Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Quantity by Application (2026-2031) & (K Units)

Table 61. Asia-Pacific Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Quantity by Region (2020-2025) & (K Units)

Table 62. Asia-Pacific Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Quantity by Region (2026-2031) & (K Units)

Table 63. Asia-Pacific Idiopathic Pulmonary Fibrosis (IPF) Drug Consumption Value by Region (2020-2025) & (USD Million)

Table 64. Asia-Pacific Idiopathic Pulmonary Fibrosis (IPF) Drug Consumption Value by Region (2026-2031) & (USD Million)

Table 65. South America Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Quantity by Type (2020-2025) & (K Units)

Table 66. South America Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Quantity by Type (2026-2031) & (K Units)

Table 67. South America Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Quantity by Application (2020-2025) & (K Units)

Table 68. South America Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Quantity by Application (2026-2031) & (K Units)

Table 69. South America Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Quantity by Country (2020-2025) & (K Units)

Table 70. South America Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Quantity by Country (2026-2031) & (K Units)

Table 71. South America Idiopathic Pulmonary Fibrosis (IPF) Drug Consumption Value by Country (2020-2025) & (USD Million)

Table 72. South America Idiopathic Pulmonary Fibrosis (IPF) Drug Consumption Value by Country (2026-2031) & (USD Million)

Table 73. Middle East & Africa Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Quantity by Type (2020-2025) & (K Units)

Table 74. Middle East & Africa Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Quantity by Type (2026-2031) & (K Units)

Table 75. Middle East & Africa Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Quantity by Application (2020-2025) & (K Units)

Table 76. Middle East & Africa Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Quantity by Application (2026-2031) & (K Units)

Table 77. Middle East & Africa Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Quantity by Country (2020-2025) & (K Units)

Table 78. Middle East & Africa Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Quantity

by Country (2026-2031) & (K Units)

Table 79. Middle East & Africa Idiopathic Pulmonary Fibrosis (IPF) Drug Consumption Value by Country (2020-2025) & (USD Million)

Table 80. Middle East & Africa Idiopathic Pulmonary Fibrosis (IPF) Drug Consumption Value by Country (2026-2031) & (USD Million)

Table 81. Idiopathic Pulmonary Fibrosis (IPF) Drug Raw Material

Table 82. Key Manufacturers of Idiopathic Pulmonary Fibrosis (IPF) Drug Raw Materials

Table 83. Idiopathic Pulmonary Fibrosis (IPF) Drug Typical Distributors

Table 84. Idiopathic Pulmonary Fibrosis (IPF) Drug Typical Customers

## List Of Figures

### LIST OF FIGURES

Figure 1. Idiopathic Pulmonary Fibrosis (IPF) Drug Picture

Figure 2. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Revenue by Type, (USD Million), 2020 & 2024 & 2031

Figure 3. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Revenue Market Share by Type in 2024

Figure 4. Nintedanib Examples

Figure 5. Pirfenidone Examples

Figure 6. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Consumption Value by Application, (USD Million), 2020 & 2024 & 2031

Figure 7. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Revenue Market Share by Application in 2024

Figure 8. Hospital Examples

Figure 9. Clinics Examples

Figure 10. Others Examples

Figure 11. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Consumption Value, (USD Million): 2020 & 2024 & 2031

Figure 12. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Consumption Value and Forecast (2020-2031) & (USD Million)

Figure 13. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Quantity (2020-2031) & (K Units)

Figure 14. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Price (2020-2031) & (US\$/Unit)

Figure 15. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Quantity Market Share by Manufacturer in 2024

Figure 16. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Revenue Market Share by Manufacturer in 2024

Figure 17. Producer Shipments of Idiopathic Pulmonary Fibrosis (IPF) Drug by Manufacturer Sales (\$MM) and Market Share (%): 2024

Figure 18. Top 3 Idiopathic Pulmonary Fibrosis (IPF) Drug Manufacturer (Revenue) Market Share in 2024

Figure 19. Top 6 Idiopathic Pulmonary Fibrosis (IPF) Drug Manufacturer (Revenue) Market Share in 2024

Figure 20. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Quantity Market Share by Region (2020-2031)

Figure 21. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Consumption Value Market

Share by Region (2020-2031)

Figure 22. North America Idiopathic Pulmonary Fibrosis (IPF) Drug Consumption Value (2020-2031) & (USD Million)

Figure 23. Europe Idiopathic Pulmonary Fibrosis (IPF) Drug Consumption Value (2020-2031) & (USD Million)

Figure 24. Asia-Pacific Idiopathic Pulmonary Fibrosis (IPF) Drug Consumption Value (2020-2031) & (USD Million)

Figure 25. South America Idiopathic Pulmonary Fibrosis (IPF) Drug Consumption Value (2020-2031) & (USD Million)

Figure 26. Middle East & Africa Idiopathic Pulmonary Fibrosis (IPF) Drug Consumption Value (2020-2031) & (USD Million)

Figure 27. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Quantity Market Share by Type (2020-2031)

Figure 28. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Consumption Value Market Share by Type (2020-2031)

Figure 29. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Average Price by Type (2020-2031) & (US\$/Unit)

Figure 30. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Quantity Market Share by Application (2020-2031)

Figure 31. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Revenue Market Share by Application (2020-2031)

Figure 32. Global Idiopathic Pulmonary Fibrosis (IPF) Drug Average Price by Application (2020-2031) & (US\$/Unit)

Figure 33. North America Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Quantity Market Share by Type (2020-2031)

Figure 34. North America Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Quantity Market Share by Application (2020-2031)

Figure 35. North America Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Quantity Market Share by Country (2020-2031)

Figure 36. North America Idiopathic Pulmonary Fibrosis (IPF) Drug Consumption Value Market Share by Country (2020-2031)

Figure 37. United States Idiopathic Pulmonary Fibrosis (IPF) Drug Consumption Value (2020-2031) & (USD Million)

Figure 38. Canada Idiopathic Pulmonary Fibrosis (IPF) Drug Consumption Value (2020-2031) & (USD Million)

Figure 39. Mexico Idiopathic Pulmonary Fibrosis (IPF) Drug Consumption Value (2020-2031) & (USD Million)

Figure 40. Europe Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Quantity Market Share by Type (2020-2031)

Figure 41. Europe Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Quantity Market Share by Application (2020-2031)

Figure 42. Europe Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Quantity Market Share by Country (2020-2031)

Figure 43. Europe Idiopathic Pulmonary Fibrosis (IPF) Drug Consumption Value Market Share by Country (2020-2031)

Figure 44. Germany Idiopathic Pulmonary Fibrosis (IPF) Drug Consumption Value (2020-2031) & (USD Million)

Figure 45. France Idiopathic Pulmonary Fibrosis (IPF) Drug Consumption Value (2020-2031) & (USD Million)

Figure 46. United Kingdom Idiopathic Pulmonary Fibrosis (IPF) Drug Consumption Value (2020-2031) & (USD Million)

Figure 47. Russia Idiopathic Pulmonary Fibrosis (IPF) Drug Consumption Value (2020-2031) & (USD Million)

Figure 48. Italy Idiopathic Pulmonary Fibrosis (IPF) Drug Consumption Value (2020-2031) & (USD Million)

Figure 49. Asia-Pacific Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Quantity Market Share by Type (2020-2031)

Figure 50. Asia-Pacific Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Quantity Market Share by Application (2020-2031)

Figure 51. Asia-Pacific Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Quantity Market Share by Region (2020-2031)

Figure 52. Asia-Pacific Idiopathic Pulmonary Fibrosis (IPF) Drug Consumption Value Market Share by Region (2020-2031)

Figure 53. China Idiopathic Pulmonary Fibrosis (IPF) Drug Consumption Value (2020-2031) & (USD Million)

Figure 54. Japan Idiopathic Pulmonary Fibrosis (IPF) Drug Consumption Value (2020-2031) & (USD Million)

Figure 55. South Korea Idiopathic Pulmonary Fibrosis (IPF) Drug Consumption Value (2020-2031) & (USD Million)

Figure 56. India Idiopathic Pulmonary Fibrosis (IPF) Drug Consumption Value (2020-2031) & (USD Million)

Figure 57. Southeast Asia Idiopathic Pulmonary Fibrosis (IPF) Drug Consumption Value (2020-2031) & (USD Million)

Figure 58. Australia Idiopathic Pulmonary Fibrosis (IPF) Drug Consumption Value (2020-2031) & (USD Million)

Figure 59. South America Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Quantity Market Share by Type (2020-2031)

Figure 60. South America Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Quantity

Market Share by Application (2020-2031)

Figure 61. South America Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Quantity

Market Share by Country (2020-2031)

Figure 62. South America Idiopathic Pulmonary Fibrosis (IPF) Drug Consumption Value

Market Share by Country (2020-2031)

Figure 63. Brazil Idiopathic Pulmonary Fibrosis (IPF) Drug Consumption Value  
(2020-2031) & (USD Million)

Figure 64. Argentina Idiopathic Pulmonary Fibrosis (IPF) Drug Consumption Value  
(2020-2031) & (USD Million)

Figure 65. Middle East & Africa Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Quantity  
Market Share by Type (2020-2031)

Figure 66. Middle East & Africa Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Quantity  
Market Share by Application (2020-2031)

Figure 67. Middle East & Africa Idiopathic Pulmonary Fibrosis (IPF) Drug Sales Quantity  
Market Share by Country (2020-2031)

Figure 68. Middle East & Africa Idiopathic Pulmonary Fibrosis (IPF) Drug Consumption  
Value Market Share by Country (2020-2031)

Figure 69. Turkey Idiopathic Pulmonary Fibrosis (IPF) Drug Consumption Value  
(2020-2031) & (USD Million)

Figure 70. Egypt Idiopathic Pulmonary Fibrosis (IPF) Drug Consumption Value  
(2020-2031) & (USD Million)

Figure 71. Saudi Arabia Idiopathic Pulmonary Fibrosis (IPF) Drug Consumption Value  
(2020-2031) & (USD Million)

Figure 72. South Africa Idiopathic Pulmonary Fibrosis (IPF) Drug Consumption Value  
(2020-2031) & (USD Million)

Figure 73. Idiopathic Pulmonary Fibrosis (IPF) Drug Market Drivers

Figure 74. Idiopathic Pulmonary Fibrosis (IPF) Drug Market Restraints

Figure 75. Idiopathic Pulmonary Fibrosis (IPF) Drug Market Trends

Figure 76. Porters Five Forces Analysis

Figure 77. Manufacturing Cost Structure Analysis of Idiopathic Pulmonary Fibrosis (IPF)  
Drug in 2024

Figure 78. Manufacturing Process Analysis of Idiopathic Pulmonary Fibrosis (IPF) Drug

Figure 79. Idiopathic Pulmonary Fibrosis (IPF) Drug Industrial Chain

Figure 80. Sales Channel: Direct to End-User vs Distributors

Figure 81. Direct Channel Pros & Cons

Figure 82. Indirect Channel Pros & Cons

Figure 83. Methodology

Figure 84. Research Process and Data Source

## I would like to order

Product name: Global Idiopathic Pulmonary Fibrosis (IPF) Drug Market 2025 by Manufacturers, Regions, Type and Application, Forecast to 2031

Product link: <https://marketpublishers.com/r/G6C3AC13E253EN.html>

Price: US\$ 3,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G6C3AC13E253EN.html>